Current location:Home > Non-metabolic Pipeline

Non-metabolic Pipeline

Explore our global excellence in non-metabolic care through our advanced therapeutic pipelines.
Select a category to view the latest clinical progress.
  • PHASE 1 IN CHINA
    GLR2037
    AR PROTAC for prostate cancer treatment.

     

    MoA AR PROTAC
    Indication Prostate Cancer

     

  • PHASE 1 IN CHINA
    GLR1059
    Nectin-4 antibody-drug conjugate for advanced solid tumors.

     

    MoA Nectin-4 ADC
    Indication Advanced Solid Tumors

     

  • PHASE 1 IN CHINA
    GLR1062
    Recombinant adeno-asssociated virus-based vascular endothelial growth factor antagonist for the management of neovascular age-related macular degeneration.

     

    MoA rAAV-based VEGF Antagonist
    Indication Neovascular Age-related Macular Degeneration (nAMD)

     

  • PHASE 1 IN CHINA
    GLR1023
    Secukinumab biosimilar for psoriasis treatment.

     

    MoA IL-17A mAb
    Indication Psoriasis

     

  • IND IN CHINA
    GLR1044
    Dupilumab biosimilar for atopic dermatitis treatment.

     

    MoA IL-4Rα mAb
    Indication Atopic Dermatitis